Embryonal carcinoma

Embryonal carcinoma is a highly malignant germ cell tumor that represents one of the most undifferentiated and aggressive forms of nonseminomatous germ cell neoplasms. It most commonly arises in the gonads (particularly the testes in young men), but can also occur in extragonadal sites including the mediastinum, retroperitoneum, and, more rarely, the central nervous system and liver — as reflected by the associated ICD-10 codes C71.9 (brain) and C22.7 (liver). The tumor is composed of primitive, pluripotent cells that can differentiate into other germ cell tumor components, including teratoma, yolk sac tumor, and choriocarcinoma. Embryonal carcinoma cells are characteristically positive for markers such as OCT3/4, CD30, and cytokeratins. Clinical presentation depends on the site of origin. Testicular embryonal carcinoma typically presents as a painless or painful testicular mass, sometimes accompanied by symptoms of metastatic disease such as back pain, cough, or lymphadenopathy. Extragonadal presentations may include symptoms related to mass effect at the primary site, such as headaches and neurological deficits for intracranial tumors, or abdominal pain and hepatomegaly for hepatic involvement. Elevated serum tumor markers, including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), may be present and are useful for diagnosis and monitoring. Treatment typically involves a multimodal approach. For testicular embryonal carcinoma, radical inguinal orchiectomy is the primary surgical intervention, followed by cisplatin-based combination chemotherapy (such as BEP: bleomycin, etoposide, and cisplatin), which has significantly improved survival outcomes. Retroperitoneal lymph node dissection may also be performed depending on staging and residual disease. For extragonadal embryonal carcinomas, treatment strategies are adapted based on location but generally follow similar chemotherapy principles. With modern treatment, cure rates for localized disease are high, though advanced or refractory cases carry a more guarded prognosis.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Embryonal carcinoma